Tag: downstream ADC manufacturing
Axplora Advances European Exatecan Supply Route for Topoisomerase I Inhibitor ADCs
Axplora announced the completion of its first research and development batches of exatecan, a camptothecin-class topoisomerase I inhibitor, to establish an additional European source for antibody-drug conjugate (ADC) developers [1]. The company said exatecan development and manufacture are based at its Farmabios site in Gropello Cairoli, Italy, and linked to payload-linker development and bioconjugation operations at its Novasep CDMO site in Le Mans, France [1]. Validation batches are targeted before the end of 2026, with initial GMP supply targeted for late 2027 [1].
